Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, APRIL 27, 2026
08:00 - 09:00
REGISTRATION AND MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:40
RESERVED PRESENTATION
09:40 - 10:05
LATEST ADVANCEMENTS IN MRNA FORMULATION AND DELIVERY TECHNOLOGIES
Pintu Kanjilal
Strand Therapeutics

Pintu Kanjilal

Strand Therapeutics

  • Emphasizing the need for robust delivery platforms enabling clinical mRNA therapies
  • Enumerating delivery strategies applied to achieve efficient, reliable mRNA transport
  • Affirming LNPs as preferred vehicles for mRNA drug products in development and commercialization
  • Summarizing key learnings from recent LNP programs spanning formulation and safety
10:05 - 10:10
Q&A SESSION ON ADVANCES IN MRNA FORMULATION AND DELIVERY
10:10 - 10:40
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues – don't forget your business cards!
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON MRNA
11:30 - 11:55
MECHANISMS OF ENDOSOMAL ESCAPE AND INTRACELLULAR DELIVERY MEDIATED BY LIPID NANOPARTICLE COMPONENTS
Ismail Hafez
Ionis Pharmaceuticals Inc.

Ismail Hafez

Ionis Pharmaceuticals Inc.

  • Establishing how lipid nanoparticles enable intracellular delivery of mRNA via endosomal pathways
  • Differentiating the roles of ionizable, helper, and sterol lipids in endosomal rupture and mRNA release
  • Evaluating revised models of ionizable lipid-mediated endosomal escape against current evidence
11:55 - 12:00
Q&A SESSION ON LNP ENDOSOMAL ESCAPE AND DELIVERY MECHANISMS
12:00 - 12:25
MASS PHOTOMETRY AS A NEXT-GENERATION PLATFORM FOR MULTI-ATTRIBUTE RNA THERAPEUTIC ANALYTICS
Matthew J Ranaghan
Refeyn

Matthew J Ranaghan

Refeyn

  • Characterizing native m/saRNA length, purity, aggregation and degradation in one readout
  • Measuring integrity and purity of up to 10 kb m/saRNA with under 5% error from ng of material
  • Resolving dsRNA impurity profiles directly in heterogeneous mRNA samples for decisions
12:25 - 12:30
Q&A SESSION ON MASS PHOTOMETRY FOR MULTI-ATTRIBUTE RNA ANALYTICS
12:30 - 13:30
NETWORKING LUNCH & VISITING THE MRNA EXHIBITION
13:30 - 13:55
RISK AND REWARD OF ACCELERATING MRNA THERAPEUTICS FROM DEVELOPMENT TO THE CLINIC
Marieke Zhao
Syner-G

Marieke Zhao

Syner-G

  • Identifying bottlenecks that constrain mRNA development timelines from lab to clinic
  • Defining regulatory requirements for starting materials used in mRNA manufacturing supply chains
  • Examining a case study linking starting material quality to downstream mRNA quality attributes
13:55 - 14:00
Q&A SESSION ON ACCELERATING MRNA THERAPEUTICS TO CLINIC
14:00 - 14:25
PHASE-APPROPRIATE CMC STRATEGIES FOR DEVELOPMENT OF RNA-BASED THERAPIES FOR CONCURRENT APPROVALS IN US AND EU
Rajiv Gangurde
Parexel

Rajiv Gangurde

Parexel

  • Aligning early and late-stage CMC plans across diverse RNA therapies to de-risk scale-up
  • Sequencing CMC work to stay off the critical path while regulatory guidance remains limited
  • Navigating US and EU requirements to build a global approval strategy for RNA-based therapies
14:25 - 14:30
Q&A SESSION ON PHASE-APPROPRIATE CMC FOR RNA THERAPIES
14:30 - 14:55
HIXCAP™: CAP ANALOGS RATIONALLY DESIGNED FOR IMMUNE EVASION AND TRANSLATIONAL EFFICIENCY IN MRNA THERAPEUTICS
Tao Jiang
Hongene Biotech Corporation

Tao Jiang

Hongene Biotech Corporation

  • Structuring novel 5′ cap analogs to improve translation in immunologically active environments
  • Counteracting IFIT1-mediated suppression to enhance mRNA output under inflammatory conditions
  • Positioning HiXCap™ E2 for trials after efficacy in JAWS II cells, LPS mice, and case studies
14:55 - 15:00
Q&A SESSION ON 5' CAP ANALOGS FOR MRNA TRANSLATION
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
PROBLEMS WITH LONG MRNA SYNTHESIS? – CONGESTION ON THE DNA TEMPLATE GENERATES RNA FRAGMENTS VIA POLYMERASE BUMPING
Craig Martin
University of Massachusetts

Craig Martin

University of Massachusetts

  • Investigating polymerase bumping on crowded DNA templates that generate truncated RNA
  • Quantifying how polymerase density on DNA governs collision frequency and fragment yield
  • Preventing bumping through co-tethered transcription to restore full-length mRNA output
15:55 - 16:00
Q&A SESSION ON POLYMERASE BUMPING IN MRNA SYNTHESIS
16:00 - 16:25
GENERATIVE DESIGN OF COMPLETE THERAPEUTIC MRNA MOLECULES
Aidan Riley
Gardn Biosciences

Aidan Riley

Gardn Biosciences

  • Integrating 5′ UTR, coding sequence, and 3′ UTR in one pass to optimize full-length mRNA
  • Showing optimized linear mRNA constructs outperform circular RNA in expression and in vivo utility
  • Achieving cell type specificity, lower immunogenicity, and manufacturability via end-to-end design
16:25 - 16:30
Q&A SESSION ON GENERATIVE DESIGN OF THERAPEUTIC MRNA
16:30 - 16:55
RNA THERAPEUTICS: MULTI-MODALITY POTENTIAL FROM GENE SILENCING THROUGH THERAPEUTICS
Anis H Khimani
ZeptoMetrix Corporation

Anis H Khimani

ZeptoMetrix Corporation

  • Tracing the shift from transcriptional paradigms to therapeutic applications with context
  • Surveying a broad pipeline spanning therapeutic areas and modalities across RNA medicines
  • Anticipating challenges and future opportunities for multi modal RNA therapeutics
16:55 - 17:00
Q&A SESSION ON MULTI-MODAL RNA THERAPEUTICS
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, APRIL 28, 2026
08:30 - 09:00
MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:35
DON’T WISH FOR A SECOND CHANCE AT A SUCCESSFUL GO-TO-MARKET WHEN YOU’RE SEEKING FUNDING
Ben Newcomb
Newcomb Advisors

Ben Newcomb

Newcomb Advisors

  • Strengthening go-to-market rigor to meet investor scrutiny alongside scientific validation
  • Diagnosing common GTM missteps in pricing, ICP, access, and partnerships before Series A
  • Constructing investor-ready commercialization plans to support scale, regulation, and business deals
09:35 - 09:40
Q&A SESSION ON INVESTOR-READY GO-TO-MARKET STRATEGY FOR RNA THERAPIES
09:40 - 10:05
ENGINEERED EXTRACELLULAR VESICLES ENGINEERED WITH MRNA FOR TREATMENT OF DEGENERATIVE DISC DISEASE
Wenchun Qu
Mayo Clinic

Wenchun Qu

Mayo Clinic

  • Highlighting potent immunomodulatory effects of mRNA-engineered extracellular vesicles
  • Addressing disc regeneration using mRNA-based therapeutics to restore structure and function
  • Contextualizing EV design and delivery variables that influence targeting to disc tissues
10:05 - 10:10
Q&A SESSION ON ENGINEERED EV FOR MRNA THERAPEUTICS
10:10 - 10:35
OBTAINING BROAD PATENTS IN BIOTECH
Laura A Labeots
Lathrop GPM LLP

Laura A Labeots

Lathrop GPM LLP

  • Interpreting Amgen v. Sanofi to clarify enablement under 35 USC 112(a) for biotech
  • Summarising core enablement principles that shape biological drug and antibody claim scope
  • Drafting broad, defensible claims using practical strategies and specification support
10:35 - 10:40
Q&A SESSION ON BROAD BIOTECH PATENT CLAIM STRATEGIES
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:25
ANTISENSE BASED MICROBIAL TARGETING VIA ANTIBODY-NANOPARTICLE CONJUGATES
Brandon Armstead
Brown University Health

Brandon Armstead

Brown University Health

  • Formulating antibody-targeted nanoparticles to deliver antisense oligos to septic pathogens
  • Profiling pathogen gene targets from whole-blood diagnostics to guide selective depletion plans
  • Conjugating surface antibodies to improve targeting and delivery of gene-silencing cargo
11:25 - 11:30
Q&A SESSION ON ANTISENSE NANOPARTICLE SEPSIS TARGETING
11:30 - 11:55
A NOVEL CIRCULAR RNA PLATFORM THAT PREFERENTIALLY TARGETS PROTEIN PRODUCING CELLS
Peter Weinstein
Circurna

Peter Weinstein

Circurna

  • Stabilizing thermostable ciRNA™ delivered by microneedle patches for dermal protein output
  • Administering ciRNA™ to dermis cells that drive in vivo protein production for therapy response
  • Sustaining protein expression for over a week, enabling one or two doses to reach effect
  • Translating two-dose vaccine efficacy into programs for cancer, fibrosis, autoimmune disease
11:55 - 12:00
Q&A SESSION ON CIRNA PLATFORM TARGETING PROTEIN-PRODUCING DERMAL CELLS
12:00 - 12:25
REVSELECT™ AI-POWERED 5′ UTR OPTIMIZATION DRIVING 65% HIGHER PROTEIN EXPRESSION AND ACCELERATED PATHWAYS FOR PERSONALIZED MRNA THERAPEUTICS
Molly McGlaughlin
Revolution Biomanufacturing Inc.

Molly McGlaughlin

Revolution Biomanufacturing Inc.

  • Optimizing 5′ and 3′ UTRs with AI models to refine ribosome loading and translation outcomes
  • Leveraging pretrained language models and structural features to predict translational efficiency
  • Demonstrating 65% gains in protein expression using validated UTR designs across models
  • Identifying novel IRES elements with improved precision to advance personalized mRNA use
12:25 - 12:30
Q&A SESSION ON AI-POWERED UTR OPTIMIZATION FOR MRNA
12:30 - 13:30
NETWORKING LUNCH & VISITING THE MRNA EXHIBITION
13:30 - 13:55
UNLOCKING RNA THERAPEUTICS IN CANCER AND AUTOIMMUNE DISEASE USING A REDOSABLE PEPTIDE-BASED NANOPARTICLE PLATFORM
Gilles Divita
Aanastra

Gilles Divita

Aanastra

  • Developing AI-driven peptide nanoparticles to enable targeted RNA delivery at scale
  • Expanding extrahepatic reach with PEP-NP™ peptide nanoparticles for selective mRNA delivery
  • Realizing in vivo mRNA-based CAR-T engineering using targeted peptide nanoparticles
13:55 - 14:00
Q&A SESSION ON REDOSABLE PEPTIDE NANOPARTICLE FOR MRNA DELIVERY
14:00 - 14:25
COMBINED DELIVERY OF MIR-15/16 THROUGH HUMANIZED FERRITIN NANOCAGES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Maria Vittoria Farina
Sapienza University, Rome

Maria Vittoria Farina

Sapienza University, Rome

  • Encapsulating miR-15/16 in humanized ferritin nanocages to restore tumor suppressor activity
  • Internalizing dual miRNAs via TfR1 in MEG01 CLL models to deliver cargo into cytoplasm
  • Triggering apoptosis by lowering Bcl-2 after combined miR-15a and miR-16-1 delivery
14:25 - 14:30
Q&A SESSION ON COMBINED MIR-15/16 DELIVERY BY FERRITIN NANOCAGE IN CLL
14:30 - 14:55
IMPURITY CHARACTERIZATION AND CONTROL DURING MRNA PRODUCTION
Kok-Seong Lim
Independent Consultant

Kok-Seong Lim

Independent Consultant

  • Pinpointing key impurity sources in mRNA production, including dsRNA and mRNA–lipid adducts
  • Implementing analytical methods for accurate detection and quantification of impurities
  • Reducing impurities via practical steps, in-process controls, and post-purification optimization
14:55 - 15:00
Q&A SESSION ON IMPURITY CONTROL IN mRNA PRODUCTION
15:00 - 15:15
FEEDBACK & RAFFLE DRAW
15:15 - 15:30
CLOSING REMARKS

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.